(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2010].
custom-made
TNFSF10
Origine: Souris
Hôte: HEK-293 Cells
Recombinant
> 90 % as determined by Bis-Tris PAGE, anti-tag ELISA, Western Blot and analytical SEC (HPLC)
custom-made
TNFSF10
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 90 % as determined by Bis-Tris PAGE, anti-tag ELISA, Western Blot and analytical SEC (HPLC)
Borbone, De Rosa, Siciliano, Altucci, Croce, Fusco: "Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells." dans: The Journal of clinical endocrinology and metabolism, Vol. 98, Issue 6, pp. E1031-40, (2013) (PubMed).
Koschny, Ganten, Sykora, Haas, Sprick, Kolb, Stremmel, Walczak: "TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window." dans: Hepatology (Baltimore, Md.), Vol. 45, Issue 3, pp. 649-58, (2007) (PubMed).
Ganten, Koschny, Sykora, Schulze-Bergkamen, Büchler, Haas, Schader, Untergasser, Stremmel, Walczak: "Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 8, pp. 2640-6, (2006) (PubMed).
Wissink, Verbrugge, Vink, Schader, Schaefer, Walczak, Borst, Verheij: "TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy." dans: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 80, Issue 2, pp. 214-22, (2006) (PubMed).
Pitti, Marsters, Ruppert, Donahue, Moore, Ashkenazi: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family." dans: The Journal of biological chemistry, Vol. 271, Issue 22, pp. 12687-90, (1996) (PubMed).